Numinus to Begin Trading on the OTC Under Symbol NUMIF Post published:November 19, 2021 Post category:Press Release
Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study Post published:November 19, 2021 Post category:Press Release
Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments Post published:November 19, 2021 Post category:Press Release
Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders Post published:November 18, 2021 Post category:Press Release
Filament Health Announces Co-Development and Exclusive Licensing Agreement with Entheotech Bioscience Post published:November 18, 2021 Post category:Press Release
MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test Post published:November 18, 2021 Post category:Press Release
Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director Post published:November 18, 2021 Post category:Press Release
Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods Post published:November 18, 2021 Post category:Press Release
CaaMTech Teams Up With University of Wyoming to Study Psychedelics as Treatments for Addiction Post published:November 16, 2021 Post category:Press Release
MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease Post published:November 16, 2021 Post category:Press Release